According to a recent LinkedIn post from Neuronoff Inc, the company is highlighting preclinical work demonstrating multi-site implantable pulse generator, or IPG, compatibility for its Injectrode neuromodulation platform. The post describes a needle-delivered tripolar Injectrode electrode that can connect to standard IPG connectors used in spinal cord stimulation systems.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post suggests that this configuration was evaluated in a three-month large-animal study using a remote-controlled IPG. According to the description, a single IPG was used to selectively stimulate lumbar dorsal root ganglion, peripheral nerve and sacral targets, potentially extending the range of interventional pain applications from one generator.
If this approach translates successfully into human use, investors could view it as expanding Neuronoff’s addressable market in chronic pain and neuromodulation by leveraging existing SCS-approved IPG ecosystems. Compatibility with standard industry connectors may also reduce barriers to adoption, allowing clinicians and device manufacturers to integrate the Injectrode platform without entirely new hardware infrastructure.
From a financial perspective, broader compatibility could position Neuronoff as a platform technology supplier within spinal cord, peripheral nerve and sacral neuromodulation segments. However, the post links to a press release and refers to preclinical animal work, so any commercial impact is likely contingent on successful clinical translation, regulatory clearance and reimbursement pathways over the medium to long term.